Top

BMC Pulmonary Medicine

Published in:

Open Access 01-12-2024 | Mepolizumab | Research

Adverse events of anti-IL-5 drugs in patients with eosinophilic asthma: a meta-analysis of randomized controlled trials and real-world evidence-based assessments

Authors: Wen Li, Shi-Chao Tang, Lei Jin

Published in: BMC Pulmonary Medicine | Issue 1/2024

Abstract

Background

We aimed to clarify comprehensively the safety profiles of anti-IL-5 drugs and pinpoint potential safety concerns that may arise in their post-marketing phase.

Methods

Two researchers conducted comprehensive searches of PubMed, EMBASE, Web of Science, and the Cochrane Library from inception to September 2022. Additionally, we investigated the FDA AE Reporting System for post-marketing adverse event (AE) reports related to anti-IL-5 drugs. The outcomes fulfilled the proportional reporting rate criteria and the Bayesian confidence propagation neural network.

Results

We included 24 published studies in our analysis. The anti-IL-5 treatment group showed an incidence of AEs comparable to the placebo group, and it exhibited a significantly lower frequency of serious AEs. Common AEs were asthma, nasopharyngitis, headache, upper respiratory tract infection (URTI), and bronchitis. The post-marketing data included 28,478 case reports associated with the suspect drugs and 75 suspect safety observations affecting 16 system organ classes. New suspect observations included incomplete therapeutic product effect, URTIs, and pulmonary mass in reports related to mepolizumab. Reports associated with mepolizumab and benralizumab also indicated issues with incorrect technique in device usage and product issues.

Conclusions

Individual anti-IL-5 drugs’ safety profiles largely matched their product inserts. We identified issues like improper device usage, product issue, and URTIs as potential concerns for mepolizumab and benralizumab. Additionally, all anti-IL-5 drugs showed signs of incomplete therapeutic effects.

Available only for authorised users

Bousquet J, Chanez P, Lacoste JY, Barnéon G, Ghavanian N, Enander I, Venge P, Ahlstedt S, Simony-Lafontaine J, Godard P, et al. Eosinophilic inflammation in asthma. N Engl J Med. 1990;323(15):1033–9. https://doi.org/10.1056/NEJM199010113231505.CrossRefPubMed

Mubarak B, Shakoor H and Masood F (2019) Eosinophilic asthma. Asthma - Biological Evidences. IntechOpen https://doi.org/10.5772/intechopen.84297.

McBrien CN, Menzies-Gow A. The biology of eosinophils and their role in asthma. Front Med (Lausanne). 2017;30(4):93. https://doi.org/10.3389/fmed.2017.00093.CrossRef

Cho JY, Miller M, Baek KJ, Han JW, Nayar J, Lee SY, et al. Inhibition of airway remodeling in IL-5-deficient mice. J Clin Invest. 2004;113(4):551–60. https://doi.org/10.1172/JCI19133.CrossRefPubMedPubMedCentral

Walford HH, Doherty TA. Diagnosis and management of eosinophilic asthma: a US perspective. J Asthma Allergy. 2014;11(7):53–65. https://doi.org/10.2147/JAA.S39119.CrossRef

The global asthma report 2022. Int J Tuberc Lung Dis 2022 26(Supp 1):1–104 https://doi.org/10.5588/ijtld.22.1010.

GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020 Oct 17;396(10258):1204–1222. doi: https://doi.org/10.1016/S0140-6736(20)30925-9.

Jameson JL, et al. Editors, Harrison's principles of internal medicine, 20e. New York: NY, McGraw-Hill Education; 2018.

Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. 2022. https://www.ginasthma.org/.

10.

Hanania NA, Alpan O, Hamilos DL, Condemi JJ, Reyes-Rivera I, Zhu J, et al. Omalizumab in severe allergic asthma inadequately controlled with standard therapy. Ann Intern Med. 2011;154(9):573–82. https://doi.org/10.1016/j.jaci.2004.12.314.CrossRefPubMed

11.

Corren J, Casale T, Lanier BQ, Blogg M, Reisner C, Gupta N. Omalizumab is well tolerated in adolescent/adult patients (≥12 years) with moderate-to-severe persistent asthma. J Allergy Clin Immunol. 2005;115(2):S75. https://doi.org/10.7326/0003-4819-154-9-201105030-00002.CrossRef

12.

Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368(26):2455–66. https://doi.org/10.1056/NEJMoa1304048.CrossRefPubMed

13.

Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, et al. Efficacy and safety of Dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018;378(26):2475–85. https://doi.org/10.1056/nejmoa1804093.CrossRefPubMed

14.

Corren J, Menzies-Gow A, Chupp G, Israel E, Korn S, Cook B, et al. Efficacy of Tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials. Am J Respir Crit Care Med. 2023;208(1):13–24. https://doi.org/10.1164/rccm.202210-2005OC.CrossRefPubMed

15.

Menzies-Gow A, Corren J, Bourdin A, Chupp G, Israel E, Wechsler ME, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384(19):1800–9. https://doi.org/10.1056/NEJMoa2034975.CrossRefPubMed

16.

Paton J, White J, Annandale J, Boyter A, Brown J, Cant B, et al. British guideline on the management of asthma. A national clinical guideline. 2019. https://www.brit-thoracic.org.uk/quality-improvement/guidelines/asthma/.

17.

Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009;360(10):973–84. https://doi.org/10.1056/NEJMoa0808991.CrossRefPubMedPubMedCentral

18.

Flood-Page P, Swenson C, Faiferman I, Matthews J, Williams M, Brannick L, et al. International Mepolizumab study group. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med. 2007;176(11):1062–71. https://doi.org/10.1164/rccm.200701-085OC.CrossRefPubMed

19.

Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–207. https://doi.org/10.1056/NEJMoa1403290.CrossRefPubMed

20.

Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651–9. https://doi.org/10.1016/S0140-6736(12)60988-X.CrossRefPubMed

21.

Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5(5):390–400. https://doi.org/10.1016/S2213-2600(17)30125-X.CrossRefPubMed

22.

Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189–97. https://doi.org/10.1056/NEJMoa1403291.CrossRefPubMed

23.

Bernstein JA, Virchow JC, Murphy K, Maspero JF, Jacobs J, Adir Y, et al. Effect of fixed-dose subcutaneous reslizumab on asthma exacerbations in patients with severe uncontrolled asthma and corticosteroid sparing in patients with oral corticosteroid-dependent asthma: results from two phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2020;8(5):461–74. https://doi.org/10.1016/S2213-2600(19)30372-8.CrossRefPubMed

24.

Castro M, Mathur S, Hargreave F, Boulet LP, Xie F, Young J, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011;184(10):1125–32. https://doi.org/10.1164/rccm.201103-0396OC.CrossRefPubMed

25.

Corren J, Weinstein S, Janka L, Zangrilli J, Garin M. Phase 3 study of Reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts. Chest. 2016;150(4):799–810. https://doi.org/10.1016/j.chest.2016.03.018.CrossRefPubMed

26.

Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355–66. https://doi.org/10.1016/S2213-2600(15)00042-9.CrossRefPubMed

27.

Bjermer L, Lemiere C, Maspero J, Weiss S, Zangrilli J, Germinaro M. Reslizumab for inadequately controlled asthma with elevated blood eosinophil levels: a randomized phase 3 study. Chest. 2016;150(4):789–98. https://doi.org/10.1016/j.chest.2016.03.032.CrossRefPubMed

28.

Harrison TW, Chanez P, Menzella F, Canonica GW, Louis R, Cosio BG, et al. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. Lancet Respir Med. 2021;9(3):260–74. https://doi.org/10.1016/S2213-2600(20)30414-8.CrossRefPubMed

29.

FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128–41. https://doi.org/10.1016/S0140-6736(16)31322-8.CrossRefPubMed

30.

Ferguson GT, FitzGerald JM, Bleecker ER, Laviolette M, Bernstein D, LaForce C, et al. Benralizumab for patients with mild to moderate, persistent asthma (BISE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2017;5(7):568–76. https://doi.org/10.1016/S2213-2600(17)30190-X.CrossRefPubMed

31.

Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115–27. https://doi.org/10.1016/S0140-6736(16)31324-1.CrossRefPubMed

32.

Nowak RM, Parker JM, Silverman RA, Rowe BH, Smithline H, Khan F, et al. A randomized trial of benralizumab, an antiinterleukin 5 receptor α monoclonal antibody, after acute asthma. Am J Emerg Med. 2015;33(1):14–20. https://doi.org/10.1016/j.ajem.2014.09.036.CrossRefPubMed

33.

Castro M, Wenzel SE, Bleecker ER, Pizzichini E, Kuna P, Busse WW, et al. Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med. 2014;2(11):879–90. https://doi.org/10.1016/S2213-2600(14)70201-2.CrossRefPubMed

34.

Zeitlin PL, Leong M, Cole J, Mallory RM, Shih VH, Olsson RF, et al. Benralizumab does not impair antibody response to seasonal influenza vaccination in adolescent and young adult patients with moderate to severe asthma: results from the phase IIIb ALIZE trial. J Asthma Allergy. 2018;20(11):181–92. https://doi.org/10.2147/JAA.S172338.CrossRef

35.

Park HS, Kim MK, Imai N, Nakanishi T, Adachi M, Ohta K, et al. A phase 2a study of Benralizumab for patients with eosinophilic asthma in South Korea and Japan. Int Arch Allergy Immunol. 2016;169(3):135–45. https://doi.org/10.1159/000444799.CrossRefPubMed

36.

Panettieri RA Jr, Welte T, Shenoy KV, Korn S, Jandl M, Kerwin EM, et al. Onset of effect, changes in airflow obstruction and lung volume, and health-related quality of life improvements with Benralizumab for patients with severe eosinophilic asthma: phase IIIb randomized, controlled trial (SOLANA). J Asthma Allergy. 2020;17(13):115–26. https://doi.org/10.2147/JAA.S240044.CrossRef

37.

Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, et al. Oral glucocorticoid-sparing effect of Benralizumab in severe asthma. N Engl J Med. 2017;376(25):2448–58. https://doi.org/10.1056/NEJMoa1703501.CrossRefPubMed

38.

Laviolette M, Gossage DL, Gauvreau G, Leigh R, Olivenstein R, Katial R, et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol. 2013;132(5):1086–1096.e5. https://doi.org/10.1016/j.jaci.2013.05.020.CrossRefPubMedPubMedCentral

39.

Jackson DJ, Bacharier LB, Gergen PJ, Gagalis L, Calatroni A, Wellford S, et al. US National Institute of allergy and infectious Disease's Inner City asthma consortium. Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet. 2022;400(10351):502–11. https://doi.org/10.1016/S0140-6736(22)01198-9.CrossRefPubMedPubMedCentral

40.

Moore WC, Kornmann O, Humbert M, Poirier C, Bel EH, Kaneko N, et al. Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study). Eur Respir J. 2022;59(1):2100396. https://doi.org/10.1183/13993003.00396-2021.CrossRefPubMedPubMedCentral

41.

Reslizumab. Summary of Product Characteristics. Teva Pharmaceuticals Ltd. Updated 06-Jan-2022.

42.

Benralizumab. Summary of Product Characteristics. AstraZeneca UK Limited. Updated 16-Nov-2022.

43.

Mepolizumab. Summary of Product Characteristics. GlaxoSmithKline UK. Updated 24-Jun-2022.

44.

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;29(372):n71. https://doi.org/10.1136/bmj.n71.CrossRef

45.

The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) (2016). Good Clinical Practice.

46.

JPT H, Savović J, Page MJ, Elbers RG, JAC S. Chapter 8: assessing risk of bias in a randomized trial. In: JPT H, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane handbook for systematic reviews of interventions version 6.3 Cochrane; 2022. Available from: www.training.cochrane.org/handbook.

47.

EudraVigilance Expert Working Group. Guideline on the use of statistical signal detection in EudraVigilance. 2008. https://www.ema.europa.eu/.

48.

Sun L, Sun S, Wang T, Li J, Lin J. Parallel ADR detection based on spark and BCPNN. Tsinghua Sci Technol. 2019;24(2):195–206. https://doi.org/10.26599/TST.2018.9010074.CrossRef

49.

Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998;54(4):315–21. https://doi.org/10.1007/s002280050466.CrossRefPubMed

50.

He LL, Zhang L, Jiang L, Xu F, Fei DS. Efficacy and safety of anti-interleukin-5 therapy in patients with asthma: a pairwise and Bayesian network meta-analysis. Int Immunopharmacol. 2018;64:223–31. https://doi.org/10.1016/j.intimp.2018.08.031.CrossRefPubMed

51.

Wang FP, Liu T, Lan Z, Li SY, Mao H. Efficacy and safety of anti-Interleukin-5 therapy in patients with asthma: a systematic review and Meta-analysis. PLoS One. 2016;11(11):e0166833. https://doi.org/10.1371/journal.pone.0166833.CrossRefPubMedPubMedCentral

52.

Akenroye A, Lassiter G, Jackson JW, Keet C, Segal J, Alexander GC, et al. Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: a Bayesian network meta-analysis. J Allergy Clin Immunol. 2022;150(5):1097–1105.e12. https://doi.org/10.1016/j.jaci.2022.05.024.CrossRefPubMedPubMedCentral

53.

Munno I, Centonze V, Marinaro M, Bassi A, Lacedra G, Causarano V, et al. Cytokines and migraine: increase of IL-5 and IL-4 plasma levels. Headache. 1998;38(6):465–7. https://doi.org/10.1046/j.1526-4610.1998.3806465.x.CrossRefPubMed

54.

Aydın M, Demir CF, Arıkanoğlu A, Bulut S, İlhan N. Plasma cytokine levels in Migraineurs during and outside of attacks. Eur J Gen Med. 2015;12(4):307–12. https://doi.org/10.15197/ejgm.01255.CrossRef

55.

Takatsu K. Interleukin-5 and IL-5 receptor in health and diseases. Proc Jpn Acad Ser B Phys Biol Sci. 2011;87(8):463–85. https://doi.org/10.2183/pjab.87.463.ADSCrossRefPubMedPubMedCentral

56.

Smith T, Cunningham-Rundles C. Primary B-cell immunodeficiencies. Hum Immunol. 2019;80(6):351–62. https://doi.org/10.1016/j.humimm.2018.10.015.CrossRefPubMed

57.

Brook I. Role of encapsulated Bacteroides sp. in upper respiratory tract infection. Med Mal Infect. 1990;20:37–44.CrossRef

58.

El-Radhi AS. Fever in common infectious diseases. Clin Man Fever Child. 2019;2009:81–135. https://doi.org/10.1007/978-3-540-78598-9_5.CrossRef

59.

Liu W, Ma X, Zhou W. Adverse events of benralizumab in moderate to severe eosinophilic asthma: a meta-analysis. Med (Baltimore). 2019;98(22):e15868. https://doi.org/10.1097/MD.0000000000015868.CrossRef

60.

Mukherjee M, Aleman Paramo F, Kjarsgaard M, Salter B, Nair G, LaVigne N, et al. Weight-adjusted intravenous Reslizumab in severe asthma with inadequate response to fixed-dose subcutaneous Mepolizumab. Am J Respir Crit Care Med. 2018;197(1):38–46. https://doi.org/10.1164/rccm.201707-1323OC.CrossRefPubMed

61.

Poznanski SM, Mukherjee M, Zhao N, Huang C, Radford K, Ashkar AA, et al. Asthma exacerbations on benralizumab are largely non-eosinophilic. Allergy. 2021;76(1):375–9. https://doi.org/10.1111/all.14514.CrossRefPubMed

62.

Sehmi R, Smith SG, Kjarsgaard M, Radford K, Boulet LP, Lemiere C, et al. Role of local eosinophilopoietic processes in the development of airway eosinophilia in prednisone-dependent severe asthma. Clin Exp Allergy. 2016;46(6):793–802. https://doi.org/10.1111/cea.12695.CrossRefPubMed

Title: Adverse events of anti-IL-5 drugs in patients with eosinophilic asthma: a meta-analysis of randomized controlled trials and real-world evidence-based assessments
Authors: Wen Li
Shi-Chao Tang
Lei Jin
Publication date: 01-12-2024
Publisher: BioMed Central
Keywords: Mepolizumab
Reslizumab
Bronchial Asthma
Published in: BMC Pulmonary Medicine / Issue 1/2024
Electronic ISSN: 1471-2466
DOI: https://doi.org/10.1186/s12890-024-02885-2

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2024

A case with multiple nodules and mucosal oedema of the trachea and both bronchi induced by IgG4-related disease

A challenging diagnosis of lung cancer

Diabetes mellitus and idiopathic pulmonary fibrosis: a Mendelian randomization study

The triad of physiological challenges: investigating the intersection of sarcopenia, malnutrition, and malnutrition-sarcopenia syndrome in patients with COPD - a cross-sectional study

Unraveling the mediation role of frailty and depression in the relationship between social support and self-management among Chinese elderly COPD patients: a cross-sectional study

Association between admission heart rate and in-hospital mortality in patients with acute exacerbation of chronic obstructive pulmonary disease and respiratory failure: a retrospective cohort study

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage